West Pharmaceutical Services (NYSE:WST) Stock Gets Price Target Bump from TD Cowen

West Pharmaceutical Services (NYSE:WST) had its price target lifted by TD Cowen from $420.00 to $500.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the medical instruments supplier’s stock. TD Cowen‘s price objective would suggest a potential upside of 21.14% from the stock’s current price.

Several other equities research analysts have also recently commented on WST. Morgan Stanley raised shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $365.00 to $400.00 in a research report on Tuesday, September 22nd. UBS Group increased their price target on shares of West Pharmaceutical Services from $340.00 to $415.00 and gave the company a “buy” rating in a report on Wednesday, September 9th. Evercore reissued an “outperform” rating and issued a $425.00 target price on shares of West Pharmaceutical Services in a research report on Monday, July 27th. Barclays raised their price objective on West Pharmaceutical Services from $440.00 to $500.00 and gave the stock an “overweight” rating in a research note on Friday. Finally, KeyCorp upped their price target on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an “overweight” rating in a report on Thursday, July 2nd. Twelve research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $402.83.

West Pharmaceutical Services Trading Down 0.9%

WST stock traded down $3.94 during trading on Friday, hitting $412.73. The company had a trading volume of 1,062,315 shares, compared to its average volume of 809,136. West Pharmaceutical Services has a 12 month low of $223.83 and a 12 month high of $438.27. The stock has a market cap of $29.05 billion, a price-to-earnings ratio of 52.85, a PEG ratio of 2.83 and a beta of 1.13. The company has a quick ratio of 2.12, a current ratio of 2.82 and a debt-to-equity ratio of 0.07. The firm has a 50-day moving average price of $366.60 and a 200-day moving average price of $312.50.

West Pharmaceutical Services (NYSE:WST) last issued its earnings results on Thursday, October 29th. The medical instruments supplier reported $2.66 EPS for the quarter, beating the consensus estimate of $2.20 by $0.46. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The company had revenue of $874.50 million during the quarter, compared to analysts’ expectations of $827.12 million. During the same quarter in the previous year, the company posted $1.96 EPS. The business’s revenue for the quarter was up 8.7% compared to the same quarter last year. As a group, analysts predict that West Pharmaceutical Services will post 8.92 earnings per share for the current year.

Insider Activity

In related news, VP Annette Favorite sold 8,135 shares of the stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $340.81, for a total transaction of $2,772,489.35. Following the transaction, the vice president directly owned 16,845 shares of the company’s stock, valued at $5,740,944.45. This represents a 32.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last 90 days, insiders have sold 15,659 shares of company stock worth $5,443,749. 0.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. Cornerstone Planning Group LLC raised its position in West Pharmaceutical Services by 90.9% in the first quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 50 shares during the period. Avalon Trust Co purchased a new stake in shares of West Pharmaceutical Services in the 2nd quarter valued at about $28,000. Addison Advisors LLC bought a new stake in West Pharmaceutical Services during the second quarter valued at approximately $28,000. Raiffeisen Bank International AG increased its position in shares of West Pharmaceutical Services by 95.6% during the 2nd quarter. Raiffeisen Bank International AG now owns 133 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 65 shares during the last quarter. Finally, Elevation Wealth Partners LLC raised its position in West Pharmaceutical Services by 1,377.8% in the 2nd quarter. Elevation Wealth Partners LLC now owns 133 shares of the medical instruments supplier’s stock worth $48,000 after purchasing an additional 124 shares during the period. Institutional investors own 93.90% of the company’s stock.

More West Pharmaceutical Services News

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Q3 results exceeded expectations: West reported adjusted earnings of $2.66 per share, above the $2.20 consensus estimate, while revenue rose 8.7% year over year to $874.5 million, surpassing the $827.1 million forecast. West Reports Third-Quarter 2026 Results
• Positive Sentiment: Higher 2026 outlook: Management raised full-year revenue guidance to $3.41 billion-$3.42 billion from $3.345 billion-$3.380 billion and lifted adjusted EPS guidance to $9.38-$9.48 from $8.85-$9.05. West Pharmaceutical Services Raises Annual Outlook
• Positive Sentiment: Strong high-value product demand: High-Value Product Components sales increased 19.7% and accounted for 53% of quarterly sales, supporting margin expansion and confidence in the company’s growth mix. West Pharma Q3 Earnings Rise on HVP Strength
• Positive Sentiment: Barclays raised its price target to $500 from $440 and maintained an “overweight” rating, implying additional upside based on the referenced share price. Barclays Raises West Pharmaceutical Price Target
• Neutral Sentiment: Institutional positioning was mixed, with several large funds adding shares while others reduced or exited positions. Recent insider activity also showed sales rather than purchases, though these transactions may not reflect the company’s operating outlook.
• Negative Sentiment: Valuation remains a risk after the rally, with the stock trading at a high earnings multiple. One analysis also cautioned that declining cash flow may leave the shares overvalued if earnings growth moderates. West Stock Could Be Overvalued

About West Pharmaceutical Services

West Pharmaceutical Services, Inc develops and manufactures components and delivery systems used in the administration and packaging of injectable medicines and other healthcare products. Its offerings include elastomer closures, seals, syringe components, drug-delivery systems, and other specialized packaging components designed to support the safety, quality, and performance of pharmaceutical products.

The company also provides contract-manufacturing services for pharmaceutical, biotechnology, and medical-device customers.